2 October 2018 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NYSE: RDY) has announced the termination of a license granted to Armis Biopharma, Inc. (formerly known as CHD Bioscience, Inc.) for its investigational antibacterial product, DFA-02, for the prophylaxis of surgical site infections.
As a result of the termination, Dr. Reddy's has regained worldwide rights to DFA-02, and is currently evaluating its options to take the program forward.
DFA-02 is a combination, broad spectrum antibacterial in situ gel which is being investigated for the prophylaxis of SSIs as an adjunct to conventional preoperative antibiotic prophylaxis.
It has been studied in several phase 1 and 2 clinical studies, and has demonstrated clinical efficacy in several key segments of patients who were at high risk for SSIs.
Dr. Reddy's is an integrated pharmaceutical company. Through its three businesses, Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include USA, India, Russia and CIS countries, and Europe.